AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03638830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ftortiazinon (tablets 300 mg) full dose + Maxipim
Description: Ftortiazinon tablets 300 mg (FSBI N.F. Gamaleya NRCEM of the Ministry of Health of the Russian Federation)
Study NCT03638830 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo+Maxipim
Description: placebo
Study NCT01808222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FACBC
Description: Participants will receive a bolus of anti-\[18F\]FACBC injected IV over 1-2 minutes. The dosage will be approximately 10.0 millicuries (mCi) (3.70 x 108 becquerel (Bq)).
Study NCT02469012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination #1
Description: Sofosbuvir + Ribavirin
Study NCT02469012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination #2
Description: Sofosbuvir + Daclatasvir
Study NCT02469012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination #3
Description: Sofosbuvir + Daclatasvir + Ribavirin
Study NCT02469012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination #4
Description: Sofosbuvir + Ledipasvir
Study NCT02469012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination #5
Description: Sofosbuvir + Ledipasvir + Ribavirin
Study NCT04161105 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dry needling
Description: Dry needling is an invasive procedure involving inserting acupuncture needles directly into trigger points within muscles. The needle is partially withdrawn and re-inserted repeatedly to maximally stimulate the muscle and it's fibers.
Study NCT02900664 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PDR001
Description: Powder for solution for infusion
Study NCT00004251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole
Description: 2.5 mg of letrozole per day
Study NCT02296216 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gamma Knife radiosurgery
Description: To determine potential long-term (superior to 10 years) extra-pituitary side-effects of Gamma Knife radiosurgery in patients treated for Acromegaly
Study NCT02900664 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACZ885
Description: Solution for injection
Study NCT02900664 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CJM112
Description: Solution for infusion
Study NCT02900664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMT212
Description: Tablets
Study NCT04709159 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Call for Life Uganda
Description: Call for Life™ Uganda (C4LU) is a web-based mHealth tool that provides treatment support to patients in the form of daily or weekly pill adherence reminders, health messages, clinic appointment reminders and a remote symptom reporting service. The tool interacts with patients by text message (SMS) or using voice and tone input via keypad (Interactive Voice Response - IVR) on both analogue and smart phones.~The tool uses CONNECT FOR LIFE technology, which is on an open source platform developed by Grameen Foundation and the University of Southern Maine with financial support from the Bill and Melinda Gates Foundation. It was supported by Janssen, the Pharmaceutical Companies of Johnson and Johnson and was released under the terms of the MOTECH open source license agreement.
Study NCT02975089 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: multi-nutrient supplement
Description: 1. 1.3g/d multivitamins \& minerals powder~2. Leaflet content (same as control)
Study NCT02975089 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: multi-nutrient & soy protein supplement
Description: 1. 1.3g/d multivitamins \& minerals powder~2. 16g/d isolated soy protein powder~3. Leaflet content (same as control)
Study NCT02975089 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutrition education on balanced diet & food supplement
Description: 1. Nutrition education with a designed plate~2. 10g/d mixed nuts (cashews, pumpkin seeds, walnuts, macadamia, pine nuts, and almonds)~3. 25g/d milk powder (skimmed and calcium added)~4. Leaflet content (same as control)
Study NCT04055363 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HMO-supplemented infant formula
Description: Starter Infant Formula supplemented with 1.5g/L of Human Milk Oligosaccharides
Study NCT00816959 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: R-mabHDI and ABVD
Description: The subjects will receive R-mabHDI intravenously, separately for about 7 hours on days 1,8,15 and 22 (once a week) of every cycle. Each cycle is 4 weeks. R-mabHDI will be given for 2 cycles.~Also the subjects will receive the ABVD combination intravenously for about 1 hour on day 1 and 15 of every cycle (every 2 weeks). Each cycle is 4 weeks. ABVD will be given for 6 cycles.
Study NCT00816959 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABVD
Description: The subjects will receive the ABVD combination intravenously for about 1 hour on day 1 and 15 of every cycle (every 2 weeks). Each cycle is 4 weeks. ABVD will be given for 6 cycles.
Study NCT04208659 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Self-administration of auricular acupuncture without prosthesis
Description: Participants will insert semi-permanent acupuncture needles in their ears without the guidance of a prosthesis
Study NCT04208659 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Self-administration of auricular acupuncture with prosthesis
Description: The same participants who previous self-administered a standardized auricular acupuncture will be given custom-molded prostheses midway through the study to assess how much the prostheses facilitate insertion.
Study NCT04842110 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental: eonTM FR 1064 nm device
Description: The subject treatment area - abdomen, was treated with the 1064 nm wavelength laser.
Study NCT01645306 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Revacept
Description: single intravenous injection
Study NCT02296216 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Gamma Knife radiosurgery
Description: To determine potential long-term (superior to 10 years) extra-pituitary side-effects of Gamma Knife radiosurgery in patients treated for Acromegaly
Study NCT01817920 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: integrated multidisciplinary fall prevention program
Study NCT00900692 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dynasplint
Description: Dynamic splinting utilizes the protocols of Low-Load Prolonged Stretch (LLPS) with calibrated adjustable tension to increase Total End Range Time (TERT)to reduce contracture. The Dynasplint or Experimental group will add this therapy to their standard of care regimen
Study NCT02567708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2269557 DPI
Description: GSK2269557 will be supplied as a lactose blend in a DISKUS DPI with a unit dose strength of 500 mcg. 2 inhalations will be taken every morning before breakfast.
Study NCT02567708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo DPI
Description: Placebo will be lactose in a DISKUS DPI. 2 inhalations will be taken every morning before breakfast.
Study NCT02807610 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inj Etomidate
Description: Induction of anesthesia using IV Etomidate 0.3mg kg-1 as a single dose in patients undergoing day care procedure, after premedication with IV midazolam 0'.2mg kg-1 and IV Fentanyl 2ug kg-1.
Study NCT02807610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inj Etomidate
Description: Induction of anesthesia using IV Etomidate 0.3mg kg-1 as a single dose in patients undergoing day care procedure, after premedication with IV midazolam 0'.2mg kg-1 and IV Fentanyl 2ug kg-1.
Study NCT02807610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Injection Propofol
Description: Induction of anesthesia using IV Propofol 2mg kg-1 as a single dose in patients undergoing day care procedure, after premedication with IV midazolam 0.2mg kg-1 and IV Fentanyl 2ug kg-1
Study NCT02807610 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for Propofol
Description: After premedication with IV midazolam 0.2mg/kg and IV Fentanyl 2ug/kg Placebo was given.
Study NCT04470947 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Next generation functional drug screening
Description: High-throughput image based in-vitro drug screening on primary patient tumor cells
Study NCT04470947 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Comprehensive genomic profiling
Description: Comprehensive targeted profiling of genetic aberrations on primary patient tumor material
Study NCT01983423 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endometrial Biopsy
Description: An endometrial biopsy is performed using a sampling device known as a pipelle catheter which is introduced into the uterine cavity. The inner core is withdrawn creating suctional pressure into the hollow bore of the cavity, which allows acquisition of endometrial tissue upon rotation in the cavity. This is removed and the tissue sent for pathologic examination.
Study NCT02033447 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Magnetic Nanoparticle Injection
Study NCT01647945 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo pill
Study NCT01647945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FK506 level < 2 ng/ml
Description: FK506 goal trough blood level \< 2 ng/ml
Study NCT01647945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FK506 level 2-3 ng/ml
Description: FK506 goal trough blood level 2-3 ng/ml
Study NCT01647945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FK506 level 3-5 ng/ml
Description: FK506 goal trough blood level 3-5 ng/ml
Study NCT01445327 — intervention group
Intervention type: OTHER
Intervention: Specimen collection
Study NCT01035268 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fatty tissue transfer
Description: It will be proceeded to aspiration of the fat at the level of the natural steatomeries (hip, stomach), then in a transfer of the fat prepared in the breast by following the standardized protocol.
Study NCT00798252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Tablets, Oral, Dose escalation to a MTD from a starting dose of 850 mg/m², twice a day (BID) x 14d per cycle, until disease progression
Study NCT00798252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: IV, Dose escalation to a MTD from a starting dose of 40 mg/m², Q3wks, until disease progression
Study NCT00798252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixabepilone
Description: IV, Dose Escalation to a MTD from a starting dose of 32 mg/m², Q3wks, until disease progression
Study NCT00798252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: IV, Dose escalation to an MTD from a starting dose of 60 mg/m², Q3wks, Until disease progression
Study NCT00798252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: IV, Dose escalation to an MTD from a starting dose of Paclitaxel 135 mg/m², Q3wks, Until disease progression
Study NCT00798252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivanib alaninate
Description: Tablets, Oral, Dose escalation to a MTD from a starting dose of 400 mg, daily (QD), until disease progression
Study NCT02883036 — intervention group
Intervention type: OTHER
Intervention: blood sampling
Description: sampling after diagnosis and the mononuclear cells will be given tigecycline stimulation in vitro
Study NCT02883036 — intervention group
Intervention type: OTHER
Intervention: blood sampling
Description: sampling after register and the mononuclear cells will be given tigecycline stimulation in vitro
Study NCT00625300 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: repetitive transcranial stimulation (r-TMS)
Description: Each patient will be given 3 treatment sessions per week for 4 weeks (a total of 12 sessions). Each session is 20 minutes long and will be consisted of 20Hz stimulation trains (active) over the motor cortex and the prefrontal cortex.
Study NCT00625300 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Repetitive transcranial stimulation
Description: Sham treatment group: each patient will be given 3 treatment sessions per week for 4 weeks (a total of 12 sessions). Each session is 20 minutes long and will be consisted of sham stimulation trains over the motor cortex and the prefrontal cortex.
Study NCT00208247 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral psychotherapy
Study NCT01335347 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ND1.1
Description: adenovirus with the dsRNA adjuvant, dried and put into capsules
Study NCT01335347 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control
Description: Capsules of the same size and shape as experimental groups
Study NCT03819634 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inset II with Lantern Technology
Description: Each participant will insert the Inset II with Lantern technology and wear it for 10 days or until set failure and data will be collected on the cause of set failure. The infusion set will be used with their usual insulin pump.
Study NCT01423110 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BYM338
Study NCT01423110 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02900664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EGF816
Description: Tablets
Study NCT03732222 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stretching the diaphragm muscle
Description: Place the hands on the last costal cartilages and maintain the ascent of the ribs in the expiration.
Study NCT03732222 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Impulse technique in rotation of cervical level 3 and 4
Description: head to double chin position and then placed with neutral flexo-extension until focusing on the level of manipulation, ipsilateral lateral flexion and contralateral rotation approximately 45 degrees.
Study NCT03732222 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Combined technique of diaphragm muscle stretch and cervical rotation impulse technique level 3 and 4
Description: The same initial position, hand placement and technique guidelines will be used, cited in each of the techniques performed in the intervention 1 group and the intervention 2 group.
Study NCT03632070 — intervention group
Intervention type: BEHAVIORAL
Intervention: Data acquisition of functional abilities
Description: MRI data, motor evoked potentials, and behavior data acquisition
Study NCT04270695 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: blood flow restriction
Description: an inflatable cuff (14 cm in width \* 84 cm in length) is warped around abdominal muscles below ribs which may cause to at least 60% restriction of blood flow detected by Power Doppler ultrasonography. All participants are instructed to perform abdominal draw-in maneuver.
Study NCT04270695 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: sham blood flow restriction
Description: an inflatable cuff (14 cm in width \* 84 cm in length) is warped around abdominal muscles below ribs without inflation. All participants are instructed to perform abdominal draw-in maneuver.
Study NCT04035122 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Robotic Treatment
Description: The Lokomat is a robotic device, consisting of a powered gait orthosis with integrated computer-controlled linear actuators at each hip and knee joint, a body weight support, and a treadmill. During the Lokomat training, the patients completed at least 30 min of treatment session.
Study NCT04035122 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Treatment
Description: The standard physical treatment program consisted of general conditioning exercises, including warming up (e.g. calf, shoulder, and hand passive range of motion exercises), lower and upper extremity strengthening, postural control exercises. During the conventional training, the patients completed at least 30 min of treatment session.
Study NCT01398358 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parents of Preschoolers Series
Description: The POPS-Parent intervention consists of eight 60-90 minute lessons about preventing childhood obesity followed by four 10-minute reinforcing telephone contacts. Each lesson includes opportunities for parents to develop and practice skills, and a discussion of strategies to overcome challenges and problem-solving techniques, with an emphasis on building knowledge and self-efficacy.~The POPS-Child Intervention uses children's stories with embedded healthy nutrition themes. Five lessons (6 books) are delivered over 12 weeks. Activities include classroom cooking experiences, games/activities associated with the story's nutrition themes, and goal setting. Family Links and Parent Pages are sent home to reinforce content from school to home.
Study NCT01398358 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Incredible Years Series
Description: The Parent component (BASIC) is a group-based program (12-14 weeks, 2 hours/week) focused on enhancing parenting skills such as using effective praise, incentives, and limit-setting, and handling misbehavior. Parents complete homework activities that will be reviewed in group sessions and receive follow-up reinforcement phone calls.~For the Child component (Dinosaur School), 60, 15-20 minute lessons are delivered during Circle Time in Head Start classrooms followed by small group activities. The curriculum focuses on teaching self-regulation skills, problem-solving strategies, and prosocial behaviors.~Teachers are trained in classroom management strategies.
Study NCT00507988 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Complex Problem Solving Training
Description: 10 sessions of 45 minutes complex problem solving training over 3 weeks (including 30 minutes of computerized planning and problem-solving training with Plan-A-Day and 15 minutes group session for transfer to everyday situations)
Study NCT00507988 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Basic Cognitive Training
Description: 10 sessions over 3 weeks of 45 min basic cognitive training (including 45 min computerized training of attention, processing speed, memory)
Study NCT01118663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetadote EF (Ethylenediaminetetraacetic Acid (EDTA) - Free)
Description: Acetadote EF (Ethylenediaminetetraacetic Acid (EDTA) - Free) {new formulation} 200 mg/kg in 1000 ml diluent over 4 hours; then 100 mg/kg in 1000 ml diluent over 16 hours
Study NCT04561947 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tunnel technique
Description: After local anesthesia, the exposed root surfaces were mechanically treated with curettes. A tunnelling knives were used to prepare a split-thickness flap and create a continuous tunnel in the buccal soft tissues, following the intrasulcular incision with a #69 microblade. Split-thickness flap preparation was performed to beyond the mucogingival junction with supraperiosteal dissection by placing the tunneling knives to the soft tissue. This process was repeated by entering through the sulcus of each tooth. After the elevation of the flap, a papilla elevator placed under the flap was entered through the sulcus to mobilize the papilla, the periosteum at the base of the papilla was cut, and the full-thickness flap was elevated.
Study NCT04561947 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tunnel technique
Description: After local anesthesia, the exposed root surfaces were mechanically treated with curettes. A tunnelling knives were used to prepare a split-thickness flap and create a continuous tunnel in the buccal soft tissues, following the intrasulcular incision with a #69 microblade. Split-thickness flap preparation was performed to beyond the mucogingival junction with supraperiosteal dissection by placing the tunneling knives to the soft tissue. This process was repeated by entering through the sulcus of each tooth. After the elevation of the flap, a papilla elevator placed under the flap was entered through the sulcus to mobilize the papilla, the periosteum at the base of the papilla was cut, and the full-thickness flap was elevated.
Study NCT04561947 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Connective tissue graft
Description: CTG was harvested using the de-epithelialized connective tissue graft technique. The epithelial tissue on the outer surface of the graft was removed with a 15 blade and a 1-mm-thick graft was obtained.
Study NCT01118663 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetadote
Description: Acetadote \[old formulation\] 150 mg/kg in 200 mL diluent over 60 minutes; then Acetadote 50 mg/kg in 500 mL diluent over 4 hours; then Acetadote 100 mg/kg in 1000 mL diluent over 16 hours.
Study NCT01087203 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tanezumab
Description: 20 mg subcutaneous injection every 8 weeks x 2 doses (at Baseline and week 8)
Study NCT01087203 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo to match tanezumab 20 mg subcutaneous injection every 8 weeks x 2 doses (at Baseline and week 8)
Study NCT02650492 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Immunostimulating Interstitial Laser Thermotherapy
Description: Immunostimulating Interstitial Laser Thermotherpy (imILT) is a specific form of thermotherapy, which, in addition to destroying tumor tissue, has been optimized to cause a tumor specific immunologic response.